Global Acute Respiratory Distress Syndrome Market Size, Share, and COVID-19 Impact Analysis, By Type (Diagnosis, Treatment), By End Users (Hospitals, Speciality Clinic, Home Healthcare, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030Industry: Healthcare
Global Acute Respiratory Distress Syndrome Market Forecasts to 2030
- The Global Acute Respiratory Distress Syndrome Market Size was valued at USD 980.4 Million in 2021
- The Market is Growing at a CAGR of 7.9% from 2021 to 2030
- The Worldwide Acute Respiratory Distress Syndrome Market is expected to reach USD 2,137.6 Million by 2030
- Asia Pacific expected To Grow the fastest during the forecast period
Get more details on this report -
The Global Acute Respiratory Distress Syndrome Market is expected to reach USD 2,137.6 Million by 2030, at a CAGR of 7.9% during the forecast period 2021-2030. Despite the fact that disease prevalence is increasing and drug prices are raising, the soaring treatment costs are restraining market expansion over the anticipated year.
Acute Respiratory Distress Syndrome (ARDS) is a medical condition in which the lungs are unable to take an adequate amount of oxygen and supply it to the other vital organs. It occurs due to the accumulation of fluid in the alveoli, which prevents the lungs from filling enough amount of air, resulting in less oxygen reaching towards bloodstream. ARDS is mostly caused by other underlying causes such as sepsis, pneumonia, inhalation of harmful substances, head, chest, or another injury. The symptoms which are included in acute respiratory distress syndrome are low blood pressure, shortness of breath unusually rapid breathing, extreme tiredness, and others. The treatment which is added to treat ARDS mechanical ventilation, IV fluids, inhaled medications such as nitric oxide, and surfactants are the treatments added to treat ARDS. According to the World Health Organization survey, it states that more than 3 million people are affected by the acute respiratory distress syndrome owing to the rising air population is one of the main reasons, and the harmful gases are inhaled by the people causing many health issues.
This research report categorizes the market for global acute respiratory distress syndrome market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global acute respiratory distress syndrome market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the market.
Global Acute Respiratory Distress Syndrome Market Report Coverage
|Market Size in 2021:||USD 980.4 Million|
|Forecast Period 2021-2030 CAGR:||7.9%|
|2030 Value Projection:||USD 2,137.6 Million|
|Historical Data for:||2017-2020|
|No. of Pages:||200|
|Tables, Charts & Figures:||100|
|Segments covered:||By Type, By End Users, By Region, COVID-19 Impact Analysis|
|Companies Covered:||F. Hoffmann-La Roche Ltd, Bayer AG, Sun Pharmaceutical Industries Ltd, Novartis AG, Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited, LivaNova PLC, Besmed Health Business Corp., Armstrong Medical, Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, Terumo Medical Corporation, Getinge AB, EUROSETS|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth, & Analysis|
Get more details on this report -
Technological advancements in the treatment of respiratory distress syndrome, improved healthcare facilities with the rise in research and drug development for the treatment, and also an increase in healthcare investment day by day will all contribute profitable growth opportunities in the forecast period. Several government awareness campaigns are running to inform more people about the range of available diagnoses and treatments. Several items with superior capabilities have been introduced by major key market companies. For example, in May 2021, Medtronic announced the release of the SonarMed airway monitoring system. The technology which is used by this monitoring device to look for endotracheal tube occlusion Acoustic technology, this can also accelerate market expansion.
Limited approved drugs for the treatment of global acute respiratory distress syndrome and lack of awareness about the syndrome are the major factors restraining the revenue growth of the respiratory distress syndrome market. During the forecast period, the development of the global respiratory distress syndrome treatment may be restrained due to lack of qualified specialist who are unaware of the treatment availability for this illness.
In 2021, the treatment segment is dominating the market and is expected to grow the market during the forecast period.
Based on type, the global acute respiratory distress syndrome is segmented into diagnosis and treatment. Among these, the treatment segment is dominating the market and is expected to grow the market during the forecast period. ARDS treatment includes general supportive measures, ventilator strategies, and appropriate underlying condition treatment. Even though drug candidate research is being carried out for over a decade, only a few pharmacological therapies for ARDS have emerged.
In 2021, the hospital has projected the largest market share during the forecast period
Based on end users, the global acute respiratory distress syndrome is categorized into hospitals, speciality clinics, home healthcare, and others. Among these, the hospital segment accounted for the largest market share during the forecast period due to the favourable reimbursement policies in developed countries and more substantial patient football. Moreover, clinics are projected to slow their profitable expansion as the number of patients of acute respiratory episodes rises. Also, the launch of new products by the market players & the increasing number of hospitals by private market key players are expected to grow the market over the forecast period. The increasing number of hospital admissions and admissions in the critical care unit creates the need for ARDS treatment and thus it can drive the growth of the market.
Regional Segment Analysis of the Global Acute Respiratory Distress Syndrome Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is influencing the market over the forecast period.
Get more details on this report -
North America is expected to maintain its dominance during the forecast period owing to recent technological advancements and the availability of numerous cutting-edge pharmacological molecules to improve the therapeutic process. The incidence of rising disease conditions is dominating North American acute respiratory distress syndrome. Moreover, due to the presence of major market players, an increase in product approvals, a developed healthcare system, and a high prevalence of acute respiratory distress syndrome. Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2021 to 2030 as a result of an increase in biotechnology research and center activity.
The report offers the appropriate analysis of the key organizations/companies involved within the global acute respiratory distress syndrome market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- F. Hoffmann-La Roche Ltd
- Bayer AG
- Sun Pharmaceutical Industries Ltd
- Novartis AG
- Drägerwerk AG & Co. KGaA
- Fisher & Paykel Healthcare Limited
- LivaNova PLC
- Besmed Health Business Corp.
- Armstrong Medical
- Pfizer Inc.
- WEINMANN Emergency Medical Technology GmbH + Co. KG
- Terumo Medical Corporation
- Getinge AB
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In April 2022, the Food and Drug Administration (FDA) approved Direct Biologics to proceed with a Landmark Phase 3 clinical trial using its investigation EV Drug ExoFlow to treat acute respiratory distress syndrome (ARDS).
- In May 2021, by Medtronic, SonarMed airway monitoring system's introduction was declared to check for endotracheal tube obstruction, the system uses acoustic technology. As a result, the company’s product line has extended.
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global acute respiratory distress syndrome market based on the below-mentioned segments:
Global Acute Respiratory Distress Syndrome Market, By Type
Global Acute Respiratory Distress Syndrome Market, By End Users
- Speciality Clinics
- Home Healthcare
Global Acute Respiratory Distress Syndrome Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
Need help to buy this report?